Loading interface...

Tasigna 200 mg Capsule

Manufactured byNOVARTIS INDIA LTD
ContainsNilotinib
Description

Tasigna 200 mg Capsule is used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), a type of blood cancer that occurs due to a chromosome abnormality. This medicine is not recommended for patients below 1 year of age.

How will this medicine affect me?

Consult top doctors online and get an answer now
Chat now

Looking for a doctor?

Book an appointment with the top doctors near you
Book now

Side effects

Major & minor side effects for Tasigna 200 mg Capsule

  • Bleeding gums
  • Blurred vision
  • Bone pain
  • Dark colored urine
  • Difficulty in breathing
  • Weight loss
  • Yellowing of skin and eyes
  • Decreased urine output
  • Loss of consciousness
  • Nervousness
  • Muscle cramps
  • Bladder pain
  • Constipation
  • Hair loss
  • Depressed mood
  • Muscle stiffness
  • Slow heart beat
  • Dizziness

Uses of Tasigna 200 mg Capsule

What is it prescribed for?

  • Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)
Read More
Concerns

Commonly asked questions

  • Onset of action
    The amount of time required for this medicine to show its action is not clinically established.
  • Duration of effect
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Safe with alcohol?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is it habit forming?
    No habit-forming tendencies were reported.
  • Usage in pregnancy?
    This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before taking this medicine.
  • Usage while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. The risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may advise you to discontinue breastfeeding or to discontinue the medicine based on your clinical condition.

Allergy

This medicine is not recommended for use in patients with a known allergy to Nilotinib or any other inactive ingredients present along with it.

Hypokalemia

This medicine is not recommended for use in patients with hypokalemia (reduced potassium levels in the blood) due to the risk of worsening of the patient's condition.

Hypomagnesemia

This medicine is not recommended for use in patients with hypomagnesemia (reduced magnesium levels in the blood) due to the risk of worsening of the patient's condition.

QT interval prolongation

This medicine is not recommended for use in patients who have prolongation of QT interval due to the increased risk of worsening of the patient's condition.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before taking this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. The risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may advise you to discontinue breastfeeding or to discontinue the medicine based on your clinical condition.
General warnings

Electrolyte imbalances

Imbalances in electrolytes like sodium, potassium, and phosphates have been reported in patients receiving Tasigna 200 mg Capsule. Close monitoring of blood electrolyte levels is recommended for patients on treatment with this medicine. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.

Driving or Operating machinery

Use of this medicine may cause dizziness and blurring of vision. Hence, it is advised that you do not perform any activities that require high mental alertness like driving a vehicle or operating machinery if you experience any of these symptoms during treatment with this medicine.

Bonemarrow suppression

This medicine should be used with caution in patients having conditions like thrombocytopenia, agranulocytosis, anemia, or bone marrow suppression due to the increased risk of worsening of the patient's condition. A complete blood count should be performed before initiating treatment with this medicine. Close monitoring of blood counts is recommended during treatment with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Missed Dose

Take the missed dose as soon as you remember. If it is almost 12 hours due for the next scheduled dose, then the missed dose can be skipped. Contact your doctor for further instructions if you miss more than one scheduled dose of this medicine.

Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Escitalopram

BCG vaccine

Azithromycin

Chloroquine

Amiodarone

Cisapride

Diclofenac

Disease interactions

Pancreatitis

This medicine should be used with extreme caution in patients with pancreatitis due to the increased risk of worsening of the patient's condition. Close monitoring of blood lipase levels is recommended for such patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.

Heart and blood vessel disorder

This medicine should be used with caution in patients having a disease of the heart or the blood vessels due to the increased risk of worsening of the patient's condition. Close monitoring of heart function is recommended for such patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.

Fluid Retention and edema

This medicine should be used with caution in patients having fluid retention disorders due to the increased risk of worsening of the patient's condition. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.

Liver impairment

This medicine should be used with caution in patients suffering from liver diseases due to the increased risk of worsening of the patient's condition. Close monitoring of liver function is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition of the patient.
Food interactions
Consumption of grapefruit or grapefruit juice is not recommended during treatment with this medicine due to the increased risk of severe adverse effects.
Lab interactions
Information not available.
Take this medicine exactly as prescribed by the doctor. Do not take in larger or smaller amounts than advised/prescribed. Consult the doctor if you experience any undesirable side effects. Ensure that the course of treatment is completed. Do not stop the use of this medicine without consulting your doctor.
Miscelleneous

To be taken on an empty stomach

To be taken as instructed by doctor

Effect on sleep is not established

How it works
This medicine works by inhibiting the actions of certain abnormal proteins that cause the cancer cells to multiply. This helps in stopping the growth and spread of cancer.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Antineoplastics, BCR-ABL tyrosine kinase inhibitors

Schedule

Schedule H

[Internet]. Drugbank.ca. 2018 [cited 27 December 2018]. Available from:

https://www.drugbank.ca/drugs/DB04868

[Internet]. Pubchem.ncbi.nlm.nih.gov. 2018 [cited 27 December 2018]. Available from:

https://pubchem.ncbi.nlm.nih.gov/compound/Nilotinib

[Internet]. Hcp.novartis.com. 2018 [cited 27 December 2018]. Available from:

https://www.hcp.novartis.com/products/Tasigna/

[Internet]. Medicines.org.uk. 2018 [cited 27 December 2018]. Available from:

https://www.medicines.org.uk/emc/files/pil.6251.pdf

[Internet]. Medicines.org.uk. 2018 [cited 27 December 2018]. Available from:

https://www.medicines.org.uk/emc/files/pil.5852.pdf
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 12 Feb 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.